Sorting Evidence from Anecdote As global cannabis research accelerates, the number of published studies has never been higher, but not
Cannabis is now one of the most frequently discussed therapeutic agents in modern medicine, driven by expanding access programmes and
Cannabis Stocks Surge on Trump Video Global cannabis stocks have enjoyed a considerable, but likely temporary, run this week, after
This opinion piece was written by Calvin Rasode, Vice President, Marketing, Brains Bioceutical When Donald Trump tweets, the world pays
The European Commission (EC) is considering a major overhaul of regulations surrounding hemp across the Union, potentially marking a step
As part of the FSA’s re-energised efforts to push forward with the long-running CBD novel foods approvals process, the agency
This morning, the UK’s Food Standards Agency (FSA) announced some significant updates to its multi-year CBD Novel Foods approvals process,
Welcome to Business of Cannabis’ new weekly strategic digest tracking the financial health, market moves, and corporate developments shaping the
One of the key differences between medical cannabis and other more traditional treatments is the highly personalised nature of how each patient is affected.
DeFloria, a joint venture between Charlotte’s Web Holdings and Ajna BioSciences, is advancing toward the start of its Phase 2 clinical trial for AJA001, a cannabinoid-based (FDA) botanical drug developed to treat behavioral symptoms associated with autism spectrum disorder (ASD).
We won’t spam you
© 2024 Prohibition Holdings Ltd. All Rights Reserved.
